Amneal Pharmaceuticals, Inc. Class A AMRX 深 沪
已收盘 09-11 16:00:00 美东时间
17.01
+0.140
+0.83%
华盛通- 最 高17.11
- 今 开17.00
- 成交量 115.77万股
- 最 低 16.73
- 昨 收 16.87
- 总市值 54.32亿
- 52周最高 19.26
- 市盈率 静 76.69
- 换手率 0.36%
- 52周最低 9.49
- 委 比 41.27%
- 总股本 3.19亿
- 历史最高 24.48
- 量 比 0.66
- 振 幅 2.25%
- 历史最低 1.24
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23
Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.
09-09 23:03
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
08-26 22:01
Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition Financing
Amneal Pharmaceuticals ( ($AMRX) ) has issued an update. On August 10, 2026, Am...
08-11 06:16
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
08-04 03:46
Amneal Stockholders Approve Kashiv BioSciences Acquisition Plans
Amneal Pharmaceuticals ( ($AMRX) ) has shared an update. On July 31, 2026, Amne...
08-01 04:31
Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolio Portfolio now positioned to address the majority of U.S. iohexol injection market demand across key presentations Demonstr...
07-17 20:02
